Optimizing Treatment Strategies in the Management of Pulmonary Arterial Hypertension to Improve Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Bayer Healthcare

Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder where continuous, exceedingly high blood pressure exists in the pulmonary artery – the blood vessel that carries blood from the right ventricle of the heart into the small arteries in the lungs. As a response to the elevated resistance of blood flow, the pressure increases in the pulmonary artery and causes the right ventricle of the heart to work harder to pump blood into the lungs. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years. Additionally, PAH often leads to the onset of comorbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system.

Because of the rarity of PAH, clinicians need to understand the risk factors and symptoms of the disease, along with the importance of diagnosing the patient in the appropriate class, so as to apply treatment algorithms accordingly for pharmacologic decisions. Treatment guidelines continue to be updated to find the best treatment for the severity and individual nature of the disease in each patient. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. There are also treatments that can that target a key molecular mechanism and one of these is a director stimulator for soluble guanylate cyclase in an oral form. Optimal treatment, accurate classification, and risk stratification are keys to managing the patient’s health and costs, as incorrect classification can lead to inappropriate treatment decisions.

Upon completion of this activity, participants will be able to:

  • Analyze the latest, evidence-based guidelines for pulmonary arterial hypertension (PAH) for proper diagnosis and treatment strategies

  • Discuss the different techniques in PAH to improve and detect early diagnosis, including physical exam and imaging modalities

  • Assess the clinical evidence on the safety and efficacy of current and emerging treatment agents

  • Explore the role of combination therapy in PAH management, including risk stratification techniques that may assist in determining the most appropriate treatment

  • Examine the strategies for overcoming challenges in patients with PAH by taking a close look at the prevention of drug interactions, reducing side effects, management of comorbidities, and patient education
     

Faculty: Robert P. Frantz, MD
Professor of Medicine, Mayo Clinic College of Medicine
Director, Mayo Pulmonary Hypertension Clinic

Disclosure:

Dr. Frank serves on an advisory board for Gilead Sciences and ViiV Healthcare. He has received grant/research support from Janssen. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Bayer Healthcare

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue